jRCTs031240673招募中不适用
A Multicenter Clinical Study to Examine the Long-Term Safety of Sirolimus for Pendred Syndrome/DFNB4
未提供0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 15
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Other
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 3age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Patients aged 3 years or older at the time consent is obtained.
- •(2) Patients with Pendred syndrome or DFNB4 diagnosed according to the following diagnostic criteria, with variable inner ear impairment, or with hearing loss and pathological variants in at least one allele in the SLC26A4 gene.
- •(3) Patients eligible to take the drug.
- •(4)Patients for whom free and informed consent can be obtained in writing from the patient or a substitute.
排除标准
- •(1) Patients who, at the time of screening, the Principal Investigator considers that the audiometric hearing thresholds at the site being visited during the study period are likely to scale out at least twice at two or more of the frequencies 500, 1000 or 2000 Hz.
- •(2) Patients with a history of systemic molecular-targeted drugs related to the mTOR pathway, such as sirolimus, other mTOR inhibitors or tyrosine kinase inhibitors within the past year
- •(3) Patients with a history of hypersensitivity to sirolimus or its additives.
- •(4) Patients with fever above 38 degrees or active infection.
- •(5) HBs antigen-positive patients, HBs antibody-positive patients, HBc antibody-positive patients or patients with active hepatitis C. However, HBs antibody-positive patients may participate in the study if they are considered to have been vaccinated against hepatitis B.
- •(6) Patients with serious haematological or liver function abnormalities.
- •(7) Patients with poorly controlled dyslipidaemia.
- •Patients with serum triglycerides 500 mg/dL or more or LDL cholesterol 190 mg/dL or more despite treatment for dyslipidaemia
- •(8) Patients with severe renal dysfunction
- •Patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m2
- •(9) Patients with immunodeficiency such as HIV or primary immunodeficiency
- •(10) Patients with gastrointestinal disorders that may impair absorption of sirolimus
- •(11) Patients who have undergone surgery within 8 weeks prior to enrolment.
- •(11) Patients who have undergone surgery within 8 weeks prior to registration.
- •(12) Pregnant patients or male patients with a partner of childbearing potential who cannot agree to use contraception from the time of consent until 12 weeks after completion of Clozapine, pregnant or lactating patients, or patients who may be pregnant.
- •(13) Patients with interstitial shadows in the lungs.
- •(14) Patients who have participated in other clinical studies or trials within 6 months prior to obtaining consent
- •(15) Other patients deemed inappropriate by the principal investigator.
结局指标
主要结局
-
Adverse events and side effects (type, frequency and severity)
次要结局
- In-office pure tone audiometry(at the time of consultation)
- Mean change in hearing thresholds(over the treatment period)
- Word tone audiometry(at the time of examination)
- Dizziness and hearing interview score(at the time of examination)
- Symptom evaluation by questionnaire(at the end of the study)
研究者
相似试验
进行中（未招募）
1 期
AAEUCTR2020-004359-34-FRAssistance Publique – Hôpitaux de Paris (AP-HP)10
进行中（未招募）
1 期
/AMedDRA version: 18.0 Level: PT Classification code 10007515 Term: Cardiac arrest System Organ Class: 10007541 - Cardiac disordersEUCTR2014-002010-24-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)462
尚未招募
不适用
Premarket study to assess safety and performance of the Orion Magnetic Localization System for breast cancerBreast CancerNL-OMON24152Sirius Medical Systems B.V.30
进行中（未招募）
1 期
Eurotrophins MImetic compound for modulation of ischemia/reperfusion damage in Liver transplantation with Extended criteria Donors, a phase I/II explorative, open label, controlled, randomized studyCTIS2023-508977-10-00Mimetech S.r.l.24
进行中（未招募）
不适用
/AMedDRA version: 13.1Level: LLTClassification code 10049130Term: Back surgerySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-001396-39-DKGlostrup Hospital